Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer

Jin, Ying; Li, Zhao; Peng, Fang

doi:10.6061/clinics/2013(05)17

Cited by 62 publications

(58 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An elevated pretreatment PLR has been shown to predict poor outcome in the setting of SRS for early-stage NSCLC. Furthermore, hypoalbuminemia has been validated to serve as a marker for systemic inflammation (11), and is found to predict disease recurrence after complete resection of early-stage NSCLC (9,10). Therefore, although novel in the setting of brain SRS, our finding that markers of systemic inflammation prior to SRS predict poor outcome is supported by these previous data in different treatment settings.…”

Section: Discussionsupporting

confidence: 81%

“…Pre-treatment markers of systemic inflammation, including an elevated platelet-to-lymphocyte ratio (PLR), elevated neutrophil count, low lymphocyte count and low serum albumin concentration, have been found to predict responses to anti-neoplastic therapies and disease outcomes across multiple different malignancies (5)(6)(7)(8)(9)(10)(11). However, these markers and the role the systemic immune system plays in treatment outcomes in the setting of SRS for brain metastases have yet to be fully evaluated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases

Shaverdian

Wang

Levin-Epstein

et al. 2016

View full text Add to dashboard Cite

LC, poor initial MR, poor OS and poor intracranial control (p=0.01, p=0.01, p=0.02 and p=0.03, respectively). A lower percentage of lymphocytes predicted for poor LC and poor MR (p=0.01 and p=0.02), and an elevated PLR predicted for poor OS and poor LC (p=0.05 and p=0.04). Additionally, a lower pretreatment albumin concentration predicted for poor LC and OS (p=0.01 and p=0.03) . Conclusion: Pretreatment systemic inflammation is associated with poor outcomes post-SRS.Metastatic brain tumors are the most common intracranial neoplasms, with an incidence that continues to rise as a result of advances in neuroimaging and more effective systemic therapies. Population-based studies suggest that up to 45% of all patients with cancer develop brain metastases and that the majority of brain metastases originate from lung cancer, breast cancer and melanoma (1). The standard-of-care for brain metastases continues to evolve given innovations in radiation technology, surgical techniques and systemic therapies. However, among patients not requiring surgical resection, stereotactic radiosurgery (SRS) represents an effective and favored treatment modality with high rates of local control (2-4).Pre-treatment markers of systemic inflammation, including an elevated platelet-to-lymphocyte ratio (PLR), elevated neutrophil count, low lymphocyte count and low serum albumin concentration, have been found to predict responses to anti-neoplastic therapies and disease outcomes across multiple different malignancies (5-11). However, these markers and the role the systemic immune system plays in treatment outcomes in the setting of SRS for brain metastases have yet to be fully evaluated. There is a growing use of immunotherapy among patients with advanced cancer, and recent studies are suggesting improvements in outcomes with the combination of SRS and immunotherapy with checkpoint inhibition for treatment of brain metastases (12). Therefore, further exploring the role the systemic immune system plays in brain radiosurgery outcomes is now essential.Although the blood-brain barrier selectively isolates the central nervous system, circulating systemic immune cells are capable of migrating from the cerebral vessels into the brain parenchyma in response to various stimuli (13). Additionally, multiple studies have established that there is substantial cross-talk between systemic immune responses and inflammatory cells in the brain (14,15). Interestingly, pathological studies on brain metastases post-SRS have identified an inflammatory cellular response to be characteristic, suggesting an interaction between the immune system and SRS outcomes (16). We therefore sought to further evaluate the relationship between outcomes brain SRS and immune responses. We determined if pretreatment immune parameters associated with systemic inflammation would predict the initial response to SRS seen on the first post-treatment magnetic resonance imaging (MRI), and for local control, distant intracranial control and overall survival in the setting of SRS for b...

show abstract

Section: Discussionsupporting

confidence: 81%

mentioning

confidence: 99%

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases

Shaverdian

Wang

Levin-Epstein

et al. 2016

View full text Add to dashboard Cite

show abstract

“…6,9,27,28 It has also been shown that pretreatment lymphocytopenia predicts for poor antitumor responses in lung cancer patients receiving chemotherapy. 13 Although we do not know why we did not find these pretreatment immune parameters to predict for disease control in the setting of SBRT, this finding might potentially be related to the unique mechanisms of SBRT.…”

Section: Discussionmentioning

confidence: 98%

Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy

Shaverdian

Veruttipong

Wang

et al. 2016

Clinical Lung Cancer

View full text Add to dashboard Cite

“…Up to now, hypoalbuminemia has been reported as an independent negative prognostic factor for survival in several cancers including lung (Gupta et al, 2010), gastric (Onate-Ocana et al, 2007), colorectal and breast (Gupta et al, 2010). Also low serum albumin level was shown to be an important prognostic factor for tumor recurrence and correlate with poor survival in NSCLC patients (Jin et al, 2013;Yildirim et al, 2013). Similar to these results, in our study, we observed that patients with decreased albumins had poor survival compared to those with high albumin in patients with lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 98%

Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients

Duran¹,

İnanç²,

Karaca³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Asian Pac J Cancer Prev, 15 (15), [6449][6450][6451][6452][6453] Introduction Non-small cell lung cancer (NSCLC), which includes a broad range of lung tumors encompassing squamous cell carcinomas and adenocarcinomas as the major subtypes, is the most common cause of cancer related death (Jemal et al., 2010). In patients with lung adenocarcinoma, only a few parameters are described as a prognostic factors such as stage of disease, tumor metabolism, high GLUT1 expression and performance status (de Geus-Qei et al., 2007;Andersen et al., 2011).Serum total proteins contain albumin, globulins and other inflammatory proteins such as C-reactive protein (CRP), interleukins and tumor necrosis factors (McPherson et al., 2006). Albumin and globulins play a pivotal role in the inflammatory process . Serum albumin is also an objective parameter that reflects the degree of long-term nutrition status (Laky et al., 2007

show abstract

Prognostic impact of serum albumin levels on the recurrence of stage I non-small cell lung cancer

Cited by 62 publications

References 37 publications

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases

Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases

Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy

Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients

Contact Info

Product

Resources

About